The U.S. Food and Drug Administration (FDA) has granted accelerated approval to camizestrant (Etcamah®; AstraZeneca), previously known as AZD9833, in combination with a CDK4/6 inhibitor for patients with ER-positive, HER2-negative, locally advanced or metastatic breast cancer whose tumors develop an ESR1 mutation during first-line aromatase inhibitor and CDK4/6 inhibitor therapy. The approval includes authorization of the Guardant360 CDx assay (Guardant Health) as a companion diagnostic to detect that mutation in circulating tumor DNA.
Key Takeaways
- FDA approved Etcamah (camizestrant) despite a negative advisory vote. ODAC voted 6-3 against it in April 2026; the FDA granted accelerated approval anyway, pending confirmatory trials.
- First approval triggered by a blood test, not a scan. Camizestrant plus a CDK4/6 inhibitor is approved for HR-positive, HER2-negative breast cancer once the Guardant360 CDx ctDNA assay detects an ESR1 mutation — before radiographic progression.
- SERENA-6 showed a 56% reduction in the risk of progression. Median progression-free survival was 16.0 months with camizestrant versus 9.2 months on continued aromatase inhibitor (HR 0.44), and this finding held in extended follow-up (16.8 vs. 9.2 months; HR 0.45).
- Overall survival remains unproven. The reported OS hazard ratio (0.87; 95% CI, 0.57–1.30) isn’t statistically significant — the key gap confirmatory trials must close.
- Boxed warning for arrhythmia risk. Combining camizestrant with ribociclib or other QTc-prolonging drugs raises Torsades de Pointes risk, requiring routine ECG monitoring.
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to camizestrant (Etcamah®; AstraZeneca) in combination with a CDK4/6 inhibitor for the treatment of patients with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer whose tumors develop an ESR1 mutation during first-line therapy with an aromatase inhibitor plus a CDK4/6 inhibitor. The approval also includes use of Guardant360 CDx (Guardant Health) as a companion diagnostic to identify patients with an ESR1 mutation in circulating tumor DNA (ctDNA). [1]]2]
The decision is notable because it came only months after the FDA’s Oncologic Drugs Advisory Committee (ODAC) voted against the application. The committee’s April 2026 vote was 6 to 3 against approval, raising questions about the clinical significance of delaying a change in endocrine therapy until radiographic disease progression. [3][4][5][6]
The FDA’s decision makes camizestrant the first therapy approved in the United States specifically on the basis of detecting an emerging ESR1 mutation in ctDNA before radiographic disease progression and using that molecular finding to trigger a treatment change. [1]
ESR1 Mutations and Endocrine Resistance
ESR1 mutations are an important mechanism of acquired resistance to endocrine therapy in hormone receptor-positive breast cancer. These mutations can alter the estrogen receptor in ways that allow tumor cells to continue signaling through the pathway despite treatment with aromatase inhibitors.
According to the FDA, ESR1 mutations are detected in approximately 40% of patients with advanced or metastatic ER-positive, HER2-negative breast cancer following treatment with an aromatase inhibitor. [1]
Camizestrant is an oral selective estrogen receptor degrader (SERD) designed to bind to and degrade the estrogen receptor. The therapeutic strategy evaluated in SERENA-6 was different from the conventional approach of waiting for radiographic progression before changing endocrine therapy. Instead, patients were monitored with ctDNA, and treatment was changed when an ESR1 mutation emerged while they remained on first-line therapy. [1][7]
The premise is straightforward: if an ESR1 mutation is an early molecular signal of emerging endocrine resistance, intervening at that point might delay clinical progression rather than waiting for measurable tumor growth.
The SERENA-6 Trial and What It Showed
The FDA’s approval was based primarily on results from SERENA-6, a randomized, double-blind, placebo-controlled phase 3 trial involving patients with hormone receptor-positive, HER2-negative advanced breast cancer receiving first-line treatment with an aromatase inhibitor plus a CDK4/6 inhibitor. [7][10]
Patients underwent serial ctDNA testing during treatment. Those who developed an ESR1 mutation without evidence of radiographic disease progression were randomized to continue their existing aromatase inhibitor or switch to camizestrant while continuing their CDK4/6 inhibitor. [7][8]
The primary analysis included 315 patients who were randomized following the detection of an emergent ESR1 mutation. Camizestrant reduced the risk of disease progression or death compared with continued aromatase inhibitor therapy. Median progression-free survival was 16.0 months with camizestrant compared with 9.2 months with the aromatase inhibitor, corresponding to a hazard ratio of 0.44. [7][11]
The extended analysis subsequently reported in The Lancet Oncology confirmed the progression-free survival benefit and showed that the treatment effect was maintained with longer follow-up. The analysis also evaluated second progression-free survival, providing additional information about what happened after progression on the randomized treatment. [8]
These findings support the biological premise behind the strategy: an ESR1 mutation can be detected before radiographic progression, and changing endocrine therapy at that point can delay subsequent disease progression.
Why the Advisory Committee Said No
The ODAC vote did not dispute the finding that camizestrant improved progression-free survival in SERENA-6. Rather, the discussion centered on the clinical meaning of that improvement and whether the available evidence established that detecting ESR1 mutations and switching treatment before radiographic progression provides a sufficiently meaningful benefit for patients. [3][4][5][6]
One issue was overall survival. At the time of the FDA decision, overall survival data remained immature. The available analysis did not demonstrate a statistically significant overall survival advantage, although the FDA and AstraZeneca considered the totality of the evidence sufficient to support accelerated approval. [1][2]
Another consideration was the design of the trial itself. Patients entered the randomized portion of SERENA-6 only after an ESR1 mutation had emerged and before radiographic progression. As a result, the trial was testing a specific clinical strategy: whether switching therapy at molecular progression was better than continuing the existing endocrine therapy until radiographic progression. [7][8]
That distinction matters. The trial was not simply a comparison of camizestrant with an aromatase inhibitor in an unselected population. It was evaluating whether molecular detection of treatment resistance could be used to determine when to change treatment.
The FDA ultimately concluded that the progression-free survival results supported accelerated approval, while continued approval would depend on confirmation of clinical benefit in post-approval studies. [1]
Patient-Reported Outcomes
Patient-reported outcomes provide an important additional perspective because delaying radiographic progression is meaningful only if treatment does not impose an unacceptable burden on patients.
In the SERENA-6 patient-reported outcome analysis, global health status and quality-of-life measures were generally maintained, and the study did not identify a major deterioration in patient-reported quality of life associated with switching to camizestrant. [9]
The findings are relevant to the clinical question raised during the ODAC discussion. If treatment is changed earlier based on a molecular signal, the potential benefit should be weighed against treatment-related symptoms and the patient’s experience of therapy.
Physician Consideration
The FDA-approved indication is for camizestrant in combination with a CDK4/6 inhibitor for adults with ER-positive, HER2-negative, locally advanced or metastatic breast cancer with an ESR1 mutation whose disease has progressed following treatment with an aromatase inhibitor plus a CDK4/6 inhibitor. Guardant360 CDx is approved as a companion diagnostic for identifying patients with an ESR1 mutation in ctDNA. [1]
Camizestrant is administered orally. The recommended dose is 75 mg once daily when used in combination with a CDK4/6 inhibitor. [1][2]
The prescribing information includes important warnings and precautions, including QTc interval prolongation and the potential for cardiac arrhythmias, bradycardia, and embryo-fetal toxicity. [1]
Because camizestrant is intended for use in combination with CDK4/6 inhibitors, clinicians also need to consider the safety profile, drug-drug interactions, monitoring requirements, and dose modifications associated with the selected CDK4/6 inhibitor. [1][2]
As with any FDA-approved therapy, the complete prescribing information should be consulted before making treatment decisions.
Ongoing Studies
SERENA-6 is part of AstraZeneca’s broader clinical development program evaluating camizestrant in earlier and later stages of hormone receptor-positive breast cancer. [2][10]
The significance of SERENA-6 is not limited to the drug itself. The trial tested a treatment paradigm in which a molecular biomarker is used to identify emerging resistance and initiate a therapeutic change before conventional imaging demonstrates progression. [7][8]
This approach depends on reliable, repeated molecular testing. In SERENA-6, patients underwent serial ctDNA assessment to identify the emergence of ESR1 mutations. The use of Guardant360 CDx in the FDA-approved indication therefore connects the treatment decision directly to a validated diagnostic test. [1][10]
What Remains Open
Several questions remain. First, overall survival remains an important endpoint. Although SERENA-6 demonstrated a substantial progression-free survival benefit, longer follow-up is needed to determine whether earlier treatment switching ultimately translates into an overall survival advantage. [1]2][8]
Second, the strategy raises practical questions about how frequently patients should undergo ctDNA testing in routine clinical practice and how clinicians should respond to different patterns of molecular evolution.
Third, the clinical relevance of an emerging ESR1 mutation may depend on the treatment context, the specific mutation detected, the patient’s prior therapy, and the available treatment alternatives. SERENA-6 addressed a defined first-line treatment setting and should not automatically be generalized to every patient with an ESR1-mutated tumor. [7][8][10]
Finally, accelerated approval places additional importance on confirmatory evidence. The FDA’s decision establishes camizestrant as an available treatment option for the approved population, but continued approval will depend on verification of clinical benefit. [1]
A Narrow but Important First
The approval of camizestrant represents a significant development in the treatment of hormone receptor-positive breast cancer, but its broader significance may extend beyond the drug itself.
SERENA-6 demonstrated that an emerging molecular resistance signal can be detected before radiographic progression and used to guide a treatment change that improves progression-free survival. [7][8]
For clinicians, the immediate implication is specific: patients with the approved disease characteristics and an emerging ESR1 mutation identified through ctDNA testing now have an FDA-approved treatment option that does not require waiting for radiographic progression before changing endocrine therapy. [1]
Whether this strategy ultimately changes the broader standard of care will depend on longer-term clinical outcomes, confirmatory evidence, real-world implementation, and how clinicians incorporate serial molecular monitoring into routine breast cancer management.
For now, the camizestrant approval establishes a new regulatory and clinical precedent: molecular evidence of emerging resistance can, in a defined treatment setting, become the point at which therapy changes—even before radiographic progression.
Clinical trials
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) – ClinicalTrials.gov ID NCT04964934
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast Cancer (SERAFA-1) – ClinicalTrials.gov ID NCT07647328
A Study to Assess the Pharmacokinetics of Camizestrant (AZD9833) When Administered Alone and in Combination With Itraconazole – ClinicalTrials.gov ID NCT05551897
Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects – ClinicalTrials.gov ID NCT05790304
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer (SERENA-1b) – ClinicalTrials.gov ID NCT07427394
A Study to Investigate the Pharmacokinetics of Midazolam After Repeated Doses of Camizestrant (AZD9833) and to Investigate the Pharmacokinetics of Camizestrant When Administered Alone and in Combination With Carbamazepine in Healthy Post-Menopausal Female Participants – ClinicalTrials.gov ID NCT06547164
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast Cancer (CADILLAC) – ClinicalTrials.gov ID NCT07195227
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1) – ClinicalTrials.gov ID NCT05774951
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (CAMBRIA-2) – ClinicalTrials.gov ID NCT05952557
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01) – ClinicalTrials.gov ID NCT06380751
A Study to Investigate Efficacy and Safety With Oral AZD9833 Compared With Intramuscular Fulvestrant in Post-menopausal Women at Least 18 Years of Age With Advanced ER-positive HER2 Negative Breast Cancer (SERENA-2) – ClinicalTrials.gov ID NCT04214288
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4) – ClinicalTrials.gov ID NCT04711252
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer. (SERENA-1)
ClinicalTrials.gov ID NCT03616587
Highlights of Prescribing Information
Camizestrant (Etcamah®; AstraZeneca) [Prescribing Information]
References
[1] U.S. Food and Drug Administration. FDA Grants Accelerated Approval to a New Breast Cancer Treatment. Press release. September 4, 2026.
[2] AstraZeneca. ETCAMAH® (camizestrant) in combination with a CDK4/6 inhibitor approved in the US for 1st-line advanced HR-positive breast cancer. Press release. September 4, 2026.
[3] Friends of Cancer Research. Stakeholder Connect: Insights from the April 30 Oncologic Drugs Advisory Committee (ODAC) Meeting. May 2026.
[4] Liu A. AstraZeneca’s camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal. Fierce Biotech. April 30, 2026.
[5] Targeted Oncology. FDA’s ODAC Votes Against Camizestrant in Advanced Breast Cancer. 2026.
[6] AstraZeneca. Update on FDA Advisory Committee vote on camizestrant in combination with a CDK4/6 inhibitor for advanced HR-positive breast cancer. Press release. April 30, 2026.
[7] Bidard FC, Mayer EL, Park YH, et al. First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast Cancer. N Engl J Med. 2025. doi:10.1056/NEJMoa2502929.
[8] Turner NC, Mayer EL, Park YH, et al. Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet Oncol. 2026. doi:10.1016/S1470-2045(26)00287-1. PMID: 42442380.
[9] Mayer EL, Bidard FC, Park YH, et al. Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy. Ann Oncol. 2026;37(2):180-193. doi:10.1016/j.annonc.2025.10.006. PMID: 41125211.
[10] ClinicalTrials.gov. A Study of Camizestrant vs. Aromatase Inhibitor When Combined With CDK4/6 Inhibitor in Advanced Breast Cancer Patients Whose Tumours Have Emergence of ESR1 Mutation During First Line Treatment (SERENA-6). Identifier NCT04964934.
[11] AstraZeneca. Camizestrant reduced the risk of disease progression or death by 56% in patients with advanced HR-positive breast cancer with an emergent ESR1 tumor mutation in SERENA-6 Phase III trial. Press release. June 1, 2025.
Disclaimer: This article is intended for informational purposes for healthcare professionals and does not constitute medical advice. Prescribing information referenced here is not a complete summary of safety data; consult the full FDA-approved label before making treatment decisions. Etcamah (camizestrant) is approved under accelerated approval; continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.
Featured image: © 2019 – 2026 US FDA. Used with permission
DOI
